{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T04:36:57Z","timestamp":1648960617584},"reference-count":31,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.pcad.2018.01.011","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T12:10:11Z","timestamp":1517400611000},"page":"457-459","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease \u2013 Where Is the Moon Now?"],"prefix":"10.1016","volume":"60","author":[{"given":"Mark B.","family":"Effron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2018.01.011_bb0005","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.1983.03340130075039","article-title":"Landmark article (JAMA 1912). Clinical features of sudden obstruction of the coronary arteries. By James B. Herrick","volume":"250","author":"Herrick","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2018.01.011_bb0010","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1161\/01.CIR.45.4.903","article-title":"Use of anticoagulants in acute myocardial infarction","volume":"45","author":"Ebert","year":"1972","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.011_bb0015","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.45.4.911","article-title":"Antiplatelet aggregant agents and thrombolytic compounds in myocardial infarction: current status","volume":"45","author":"Wessler","year":"1972","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.011_bb0020","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/archinte.1976.03630110005003","article-title":"Anticoagulants in ischemic heart disease","volume":"136","author":"Rogel","year":"1976","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0025","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/archinte.1976.03630110006004","article-title":"The case for anticoagulants in acute myocardial infarction","volume":"136","author":"Modan","year":"1976","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.pcad.2018.01.011_bb0030","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.1980.03300330019023","volume":"243","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2018.01.011_bb0035","first-page":"V63","article-title":"The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group","volume":"62","author":"Breddin","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.011_bb0040","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","year":"1988","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.pcad.2018.01.011_bb0045","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM198010163031601","article-title":"Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction","volume":"303","author":"DeWood","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0050","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM198412063112301","article-title":"Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction","volume":"111","author":"Rentrop","year":"1984","journal-title":"N Engl J Med"},{"issue":"309","key":"10.1016\/j.pcad.2018.01.011_bb0055","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJM198312153092402","article-title":"Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction","volume":"L983","author":"Kennedy","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0060","first-page":"397","article-title":"Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction","volume":"1","author":"Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.011_bb0065","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"The GUSTO Investigators","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199303113281001","article-title":"A comparison of primary angioplasty with thromboiytic therapy for acute myocardial infarction","volume":"328","author":"Grines","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0075","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled trial and balloon-angioplasty\u2013controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade","volume":"352","author":"The EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.011_bb0085","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo controlled trial","volume":"356","author":"The ESPRIT Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.011_bb0090","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","volume":"96","author":"The RESTORE Investigators","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.011_bb0095","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"CURE investigators","year":"2001","journal-title":"NEJM"},{"key":"10.1016\/j.pcad.2018.01.011_bb0100","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0105","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"AHA\/ACC\/HRS guideline for the management of patients with AF: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.011_bb0110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.011_bb0115","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke prevention in atrial fibrillation study: final results","volume":"84","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.011_bb0120","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/archinte.167.3.246","article-title":"Newly detected atrial fibrillation and compliance with antithrombotic guidelines","volume":"167","author":"Glazer","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0125","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0130","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0135","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0140","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.011_bb0145","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pcad.2018.01.011_bb0150","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.pcad.2018.01.011_bb0155","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003306201830032X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003306201830032X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T10:55:03Z","timestamp":1535108103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003306201830032X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":31,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S003306201830032X"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2018.01.011","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease \u2013 Where Is the Moon Now?","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2018.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}